A Single Dose Study to Investigate the Pharmacokinetics of MK-0941 in Participants With Renal Insufficiency (MK-0941-015-02)

NCT00830791 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes

Interventions

DRUG: MK-0941 20 mg
DRUG: MK-0941 5 mg

Sponsor

Merck Sharp & Dohme LLC